#BEGIN_DRUGCARD DB06689

# AHFS_Codes:
Not Available

# ATC_Codes:
C05BB01

# Absorption:
After injection into an esophageal varix, ethanolamine oleate is cleared from the injection site within five minutes via the portal vein. Some of the medication also flows into the azygos vein through the periesophageal vein if more than 20 mL is injected.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Ethamolin
Monolate
Moramin
Neosclerol
Oldamin
Varex
Varicetin

# CAS_Registry_Number:
2272-11-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C20H41NO3

# Chemical_IUPAC_Name:
(9Z)-octadec-9-enoic acid; 2-aminoethan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2008-08-24 14:08:33 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Ethanolamine Oleate is a mild sclerosing agent.  It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

# Dosage_Forms:
Solution	Intravenous

# Drug_Category:
Sclerosing Solutions

# Drug_Interactions:
Not Available

# Drug_Reference:
10710072	Zuberi BF, Baloch Q: Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis. Am J Gastroenterol. 2000 Mar;95(3):768-71.
10805844	Meirelles-Santos JO, Carvalho AF Jr, Callejas-Neto F, Magna LA, Yamanaka A, Zeitune JM, Brandalise NA, Ferraz JG: Absolute ethanol and 5% ethanolamine oleate are comparable for sclerotherapy of esophageal varices. Gastrointest Endosc. 2000 May;51(5):573-6.
13169341	VOIGT J: [Allergy to varex (monoethanolamine oleate).] Ugeskr Laeger. 1954 Mar 25;116(12):452-7.
13997698	VOIGT J: [Fatal allergic shock after injection of Varex (monoethanolamine-oleate). On the risks of injection treatment.] Ugeskr Laeger. 1963 Jun 21;125:896-8.
14869471	PACCA ML: [Antihyaluronidase activity of monoethanolamine oleate.] Boll Soc Ital Biol Sper. 1951 Mar-Apr;27(4):576-9.
15416877	NOORDIJK JA: [Monoethanolamine oleate.] Ned Tijdschr Geneeskd. 1950 Apr 22;94(16):1110-1.
16132390	Yamamoto K, Sakaguchi H, Anai H, Tanaka T, Morimoto K, Kichikawa K, Uchida H: Sclerotherapy for simple cysts with use of ethanolamine oleate: preliminary experience. Cardiovasc Intervent Radiol. 2005 Nov-Dec;28(6):751-5.
17380286	Takuma Y, Nouso K, Takayama H, Makino Y, Saito S, Tanaka S, Ogata M, Ohta T, Kubota J, Iwamuro M: Gastric ulcer after prophylactic balloon-occluded retrograde transvenous obliteration. J Gastroenterol. 2007 Mar;42(3):257-60. Epub 2007 Mar 30.
3828735	Kang JH, Kambayashi J, Sakon M, Shiozaki H, Ogawa Y, Ohshiro T, Mori T: Mechanism of the haemostatic effect of ethanolamine oleate in the injection sclerotherapy for oesophageal varices. Br J Surg. 1987 Jan;74(1):50-3.
6332769	Seidman E, Weber AM, Morin CL, Ethier R, Lamarche JB, Guerguerian AJ, Geoffroy G, Roy CC: Spinal cord paralysis following sclerotherapy for esophageal varices. Hepatology. 1984 Sep-Oct;4(5):950-4.
6471550	Masaki M, Mitsuhashi H, Kondo Y, Suzuki S, Wada T: [Effects of embolizing agent (ethanolamine oleate; EO) on esophageal varices with special reference to endothelial injury] Nippon Shokakibyo Gakkai Zasshi. 1984 Jun;81(6):1491.
6607986	Howard ER, Stamatakis JD, Mowat AP: Management of esophageal varices in children by injection sclerotherapy. J Pediatr Surg. 1984 Feb;19(1):2-5.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ethanolamine Oleate

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C18H34O2.C2H7NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;3-1-2-4/h9-10H,2-8,11-17H2,1H3,(H,19,20);4H,1-3H2/b10-9-;

# InChI_Key:
InChIKey=KGWDUNBJIMUFAP-KVVVOXFISA-N

# Indication:
For the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02276

# LIMS_Drug_ID:
6690

# Mechanism_Of_Action:
The oleic acid component of ethanolamine oleate is responsible for the inflammatory response, and may also activate coagulation in vivo by release of tissue factor and activation of Hageman factor. The ethanolamine component, however, may inhibit fibrin clot formation by chelating calcium, so that a procoagulant action of ethanolamine oleate has not been demonstrated.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
343.5444

# Molecular_Weight_Mono:
343.308644183

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164746758

# Pharmacology:
When injected intravenously, ethanolamine oleate acts primarily by irritation of the intimal endothelium of the vein and produces a sterile dose-related inflammatory response. This results in fibrosis and possible occlusion of the vein. Ethanolamine oleate also rapidly diffuses through the venous wall and produces a dose-related extravascular inflammatory reaction.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB06689

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5282489

# PubChem_Substance_ID:
99443246

# RxList_Link:
http://www.rxlist.com/cgi/generic/ethamolin.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Monoethanolamine oleate
beta-Hydroxyethylammonium oleate
cis-9-Octadecenoic acid, ethanolamine salt

# Synthesis_Reference:
Not Available

# Toxicity:
The minimum lethal dose administered intravenously to rabbits is 130 mg/kg. Overdosage can result in severe intramural necrosis of the esophagus. Complications resulting from such overdosage have resulted in death. LD50 (intravenous) in rats is 156 mg/kg. LD50 (intravenous) in dogs is 175 mg/kg.

# Update_Date:
2013-02-08 16:24:48 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Monoethanolamine_oleate

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_1_ID:
6013

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05181

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
2519043	Yoshida T, Hayashi N, Nishimura S, Itoh T, Kawahara K, Okita K, Okazaki Y, Takemoto T: Mechanism of action of ethanolamine oleate used in injection sclerotherapy with special emphasis on the bronze varices. J Gastroenterol Hepatol. 1989;4 Suppl 1:173-5.
3828735	Kang JH, Kambayashi J, Sakon M, Shiozaki H, Ogawa Y, Ohshiro T, Mori T: Mechanism of the haemostatic effect of ethanolamine oleate in the injection sclerotherapy for oesophageal varices. Br J Surg. 1987 Jan;74(1):50-3.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4234

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Calcium ions

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
1986546	Takada K, Matsumoto A, Miyoshi H, Oshiba S: Changes in thrombin-antithrombin III complex after endoscopic injection sclerotherapy. Am J Gastroenterol. 1991 Jan;86(1):123-4.
3828735	Kang JH, Kambayashi J, Sakon M, Shiozaki H, Ogawa Y, Ohshiro T, Mori T: Mechanism of the haemostatic effect of ethanolamine oleate in the injection sclerotherapy for oesophageal varices. Br J Surg. 1987 Jan;74(1):50-3.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7208

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Coagulation Factor XII

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P00748

# Drug_Target_2_SwissProt_Name:
Not Available

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB06689
